AMGN

Q: What is the price of Amgen (AMGN) today?

The current price of Amgen (AMGN) is $ 336.79, representing a 21.46% gain over the past year. The stock began the year trading around $ 327.31 and is currently priced at $ 336.79. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Amgen (AMGN) pay dividends?

In the last year, Amgen (AMGN) distributed dividends in the month of March, totaling $ 2.52. The Dividend Yield for the last 12 months is 2.87%.

Q: Is Amgen (AMGN) a good investment?

Amgen (AMGN) is currently trading at $ 336.79 with a P/E ratio of 23.32. This represents a 2,377% premium compared to its historical average P/E. Over the past year, the stock has gained 21.46 and paid $ 2.52 in dividends, resulting in a dividend yield of 2.87%. The total shareholder return over the same period was 21.46%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

Amgen Inc.

Price

$ 336.79

return (12m)

21.46%

p/e

23.32

p/bv

19.79

DIVIDEND YIELD

2.87%

AMGN price

Amgen

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment AMGN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

2.88%

3 months

-11.41%

1 year

21.46%

2 years

17.95%

5 years

68.83%

10 years

187.05%

Fundamentals AMGN

review the fundamentals of Amgen shares

P/E

23.32

Sector: -3.99 Industry: -3.99

P/S (PSR)

4.89

Sector: -4.17 Industry: -4.17

P/BV

19.79

Sector: 2.00 Industry: 2.00

DIVIDEND YIELD (DY)

2.87%

Sector: - Industry: -

ROA

8.43%

Sector: -65.15% Industry: -65.15%

ROE

84.87%

Sector: -65.39% Industry: -65.39%

ROIC

13.89%

Sector: -2,913.92% Industry: -2,913.92%

NET MARGIN

20.96%

Sector: -40.35% Industry: -40.35%

GROSS MARGIN

68.26%

Sector: 36.51% Industry: 36.51%

OPERATING MARGIN

28.39%

Sector: -39.30% Industry: -39.30%

EV/EBITDA

10.91

Sector: -4.10 Industry: -4.10

EV/EBIT

15.44

Sector: -4.18 Industry: -4.18

PRICE-TO-ASSETS

1.97

Sector: 1.47 Industry: 1.47

BVPS

17.02

Sector: 1.88 Industry: 1.88

EPS

14.44

Sector: -2.14 Industry: -2.14

EQUITY-TO-ASSETS RATIO

0.10

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.90

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

7.46%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

5.77%

Sector: - Industry: -

FAIR VALUE OF Amgen ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current Price

$ 336.79

Fair Value

$ 74.36

Upside Return potential.

-77.92%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals AMGN

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	25.65	6.65	25.92%	2.32%	$ 539.72 B	21.83%
PFE	19.57	1.62	8.29%	6.68%	$ 146.58 B	11.83%
ABBV	106.01	-58.28	-54.98%	3.10%	$ 385.36 B	5.79%
NVO	10.68	6.45	60.40%	4.09%	$ 202.51 B	37.15%
MRK	32.85	6.39	19.45%	2.80%	$ 293.48 B	13.59%
AZN	27.68	6.07	21.93%	1.72%	$ 287.60 B	17.19%
GILD	18.12	7.13	39.33%	2.37%	$ 166.96 B	30.99%
BMY	16.02	5.80	36.19%	4.37%	$ 116.53 B	15.01%
ZTS	12.27	10.03	81.75%	2.64%	$ 32.42 B	27.79%
REGN	14.45	2.03	14.08%	0.58%	$ 63.94 B	29.65%
HALO	22.51	35.75	158.82%	0.00%	$ 7.85 B	23.13%
MCK	19.02	-108.61	-570.98%	0.43%	$ 90.58 B	1.18%
HRMY	12.58	2.01	16.00%	0.00%	$ 1.83 B	16.20%
VRTX	26.20	5.87	22.41%	0.00%	$ 113.68 B	35.51%
CAH	29.74	-17.31	-58.20%	1.04%	$ 46.25 B	0.62%
ADMA	11.39	4.82	42.37%	0.00%	$ 1.88 B	32.43%
BIIB	21.00	1.54	7.36%	0.00%	$ 28.81 B	13.81%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

AMGN Historical Dividends

current DY: 2.87%

5-year average DY: 3.27%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	05/14/2026	06/05/2026	2,52000000
Dividends	02/12/2026	03/06/2026	2,52000000
Dividends	11/20/2025	12/12/2025	2,38000000
Dividends	08/21/2025	09/12/2025	2,38000000
Dividends	05/15/2025	06/06/2025	2,38000000
Dividends	02/13/2025	03/07/2025	2,38000000
Dividends	11/15/2024	12/09/2024	2,25000000
Dividends	08/15/2024	09/06/2024	2,25000000
Dividends	05/15/2024	06/07/2024	2,25000000
Dividends	02/14/2024	03/07/2024	2,25000000
Dividends	11/15/2023	12/08/2023	2,13000000
Dividends	08/16/2023	09/08/2023	2,13000000
Dividends	05/16/2023	06/08/2023	2,13000000
Dividends	02/13/2023	03/08/2023	2,13000000
Dividends	11/15/2022	12/08/2022	1,94000000
Dividends	08/16/2022	09/08/2022	1,94000000
Dividends	05/13/2022	06/08/2022	1,94000000
Dividends	02/11/2022	03/08/2022	1,94000000
Dividends	11/12/2021	12/08/2021	1,76000000
Dividends	08/13/2021	09/08/2021	1,76000000
Dividends	05/13/2021	06/08/2021	1,76000000
Dividends	02/11/2021	03/08/2021	1,76000000
Dividends	11/12/2020	12/08/2020	1,60000000
Dividends	08/13/2020	09/08/2020	1,60000000
Dividends	05/14/2020	06/08/2020	1,60000000
Dividends	02/12/2020	03/06/2020	1,60000000
Dividends	11/13/2019	12/06/2019	1,45000000
Dividends	08/13/2019	09/06/2019	1,45000000
Dividends	05/15/2019	06/07/2019	1,45000000
Dividends	02/13/2019	03/08/2019	1,45000000
Dividends	11/14/2018	12/07/2018	1,32000000
Dividends	08/15/2018	09/07/2018	1,32000000
Dividends	05/15/2018	06/08/2018	1,32000000
Dividends	02/13/2018	03/08/2018	1,32000000
Dividends	11/15/2017	12/08/2017	1,15000000
Dividends	08/15/2017	09/08/2017	1,15000000
Dividends	05/15/2017	06/08/2017	1,15000000
Dividends	02/13/2017	03/08/2017	1,15000000
Dividends	11/14/2016	12/08/2016	1,00000000
Dividends	08/15/2016	09/08/2016	1,00000000
Dividends	05/13/2016	06/08/2016	1,00000000
Dividends	02/12/2016	03/08/2016	1,00000000
Dividends	11/12/2015	12/07/2015	0,79000000
Dividends	08/13/2015	09/08/2015	0,79000000
Dividends	05/12/2015	06/05/2015	0,79000000
Dividends	02/10/2015	03/06/2015	0,79000000
Dividends	11/11/2014	12/05/2014	0,61000000
Dividends	08/12/2014	09/05/2014	0,61000000
Dividends	05/13/2014	06/06/2014	0,61000000
Dividends	02/11/2014	03/07/2014	0,61000000
Dividends	11/12/2013	12/06/2013	0,47000000
Dividends	08/14/2013	09/06/2013	0,47000000
Dividends	05/14/2013	06/07/2013	0,47000000
Dividends	02/11/2013	03/07/2013	0,47000000
Dividends	11/13/2012	12/07/2012	0,36000000
Dividends	08/14/2012	09/07/2012	0,36000000
Dividends	05/14/2012	06/07/2012	0,36000000
Dividends	02/13/2012	03/07/2012	0,36000000
Dividends	11/15/2011	12/08/2011	0,28000000
Dividends	08/16/2011	09/08/2011	0,28000000

ABOUT Amgen

Amgen Inc.

Average Investor10 user rating

4.0 (45 people)

United States

46 years

Founded: 1980

1983

Time since IPO - 43 years

19.200

Employees

Amgen Inc. operates in the Healthcare sector, within the Biotechnology industry. Founded in 1980 in the United States, the company focuses on developing biologic medicines using advanced genetic and molecular technologies.

Amgen researches, manufactures, and commercializes therapies targeting chronic and complex diseases.

Its portfolio includes treatments in:

Oncology.
Nephrology.
Cardiovascular diseases.
Inflammation and immunology.
Bone health.
Biosimilar medicines.

The company serves hospitals, healthcare systems, specialty clinics, and pharmaceutical distributors across North America, Europe, Asia-Pacific, and Latin America.

Amgen’s performance is influenced by clinical trial outcomes, patent protection, regulatory approvals, competition from other biopharmaceutical companies, and biosimilar market expansion.

The company operates manufacturing facilities and research centers in multiple countries, supported by large-scale biologics production capabilities and global cold-chain distribution systems.

Amgen shares trade on the Nasdaq Stock Market under the ticker AMGN.

History and Development

Amgen was founded in 1980 in California under the name Applied Molecular Genetics, with the objective of applying recombinant DNA technology to develop innovative therapies.

In its early years, the company focused on building research capabilities and advancing its clinical pipeline.

Following its public listing in the early 1980s, Amgen expanded its research investment and introduced pioneering biologic treatments that strengthened its position in the biotechnology sector.

Over the decades, the company diversified into new therapeutic areas and expanded internationally through acquisitions and strategic partnerships.

In recent years, Amgen has emphasized biosimilar expansion, next-generation biologics, and advanced genetic platforms, while adapting to regulatory and competitive pressures in global pharmaceutical markets.

Additional Information

Amgen Inc. (United States) is listed on the Nasdaq and has a market capitalization of $181.87 Billions, with shareholders equity totaling $9.19 Billions.

The company employs approximately 19.200 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Amgen Inc. reported $37.22 Billions in revenue, generating net income of $7.80 Billions.

Key financial metrics include a P/E ratio of 23.32, a price-to-book (P/B) ratio of 19.79, and a trailing twelve-month dividend yield of 2.87%.

The company trades under the ticker AMGN.

Market cap

$ 181.87 Billions

Net worth

$ 9.19 Billions

$ 9,190,000,000.00

Assets

$ 92.50 Billions

$ 92,504,000,000.00

Total Shares Outstanding

540.00 Millions

540,000,000

Average Daily Trading Volume

$ 2.67 Millions

$ 2,674,864.00

Sector

Health Care

Industry

Biotechnology

AMGN

revenue by Business Segment Amgen

Revenue by Region Amgen

AMGN revenue and profits

Financial Results AMGN

DRAG THE FRAME TO SEE MORE DATA

AMGN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 742.44 3,71% (12M)

P/E

19.02

0.43%

ROE

-570.98%

P/BV

-108.61

CAH - Cardinal Health

$ 196.80 29,22% (12M)

P/E

29.74

1.04%

ROE

-58.20%

P/BV

-17.31

JNJ - Johnson & Johnson

$ 225.33 50,10% (12M)

P/E

25.65

2.32%

ROE

25.92%

P/BV

6.65

MRK - Merck & Co.

$ 118.72 61,24% (12M)

P/E

32.85

2.80%

ROE

19.45%

P/BV

6.39

AZN - AstraZeneca

$ 185.67 31,33% (12M)

P/E

27.68

1.72%

ROE

21.93%

P/BV

6.07

ABBV - AbbVie

$ 217.72 20,70% (12M)

P/E

106.01

3.10%

ROE

-54.98%

P/BV

-58.28

NVO - Novo Nordisk

$ 45.58 --33,17% (12M)

P/E

10.68

4.09%

ROE

60.40%

P/BV

6.45

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 742.44 3,71% (12 M)

P/L

19.02

0.43%

ROE

-570.98%

P/VP

-108.61

CAH - Cardinal Health

$ 196.80 29,22% (12 M)

P/L

29.74

1.04%

ROE

-58.20%

P/VP

-17.31

JNJ - Johnson & Johnson

$ 225.33 50,10% (12 M)

P/L

25.65

2.32%

ROE

25.92%

P/VP

6.65

MRK - Merck & Co.

$ 118.72 61,24% (12 M)

P/L

32.85

2.80%

ROE

19.45%

P/VP

6.39

AZN - AstraZeneca

$ 185.67 31,33% (12 M)

P/L

27.68

1.72%

ROE

21.93%

P/VP

6.07

ABBV - AbbVie

$ 217.72 20,70% (12 M)

P/L

106.01

3.10%

ROE

-54.98%

P/VP

-58.28

NVO - Novo Nordisk

$ 45.58 --33,17% (12 M)

P/L

10.68

4.09%

ROE

60.40%

P/VP

6.45

Frequently Asked Questions

What is the price of Amgen (AMGN) today?

The current price of Amgen (AMGN) is $ 336.79, representing a 21.46% gain over the past year. The stock began the year trading around $ 327.31 and is currently priced at $ 336.79. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Amgen (AMGN) pay dividends?

In the last year, Amgen (AMGN) distributed dividends in the month of March, totaling $ 2.52. The Dividend Yield for the last 12 months is 2.87%.

Is Amgen (AMGN) a good investment?

Amgen (AMGN) is currently trading at $ 336.79 with a P/E ratio of 23.32. This represents a 2,377% premium compared to its historical average P/E. Over the past year, the stock has gained 21.46 and paid $ 2.52 in dividends, resulting in a dividend yield of 2.87%. The total shareholder return over the same period was 21.46%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Amgen (AMGN) stock?

You can buy Amgen (AMGN) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol AMGN and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Amgen (AMGN) yield today?

Over the past month, Amgen (AMGN) has returned 2.88% — 21.46% over the past year, and 68.83% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 9.66 per share in dividends, resulting in a dividend yield of 2.87%.

If you were to purchase 100 shares of Amgen (AMGN) today at the current price of $ 336.79 your total investment would be $ 33,679.00.

Based on historical performance, the investment would have grown to approximately:

$ 40,906.51 after 1 year
$ 56,860.26 after 5 years
$ 96,675.57 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

AMGN

Amgen Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment AMGN

review the fundamentals of Amgen shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

current DY: 2.87%

5-year average DY: 3.27%

type

Ex - Dividend Date

payment date

value

ABOUT Amgen

Amgen Inc.

United States

46 years

1983

19.200

History and Development

Additional Information

PROFIT X PRICE AMGN

Financial Results AMGN

AMGN cash flow

Asset, Revenue and Profit Growth - AMGN

AMGN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions